Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study

Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study

ObjectiveThe aim of this study was to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) and lenvatinib in HCC patients with PVTT (Vp2-3), thus providing a safe and effective treatment strategy for advanced HCC pa...

Full description

Bibliographic Details
Main Authors:	Haohao Lu, Chuansheng Zheng, Bin Liang, Xiangwen Xia, Hongjie Fan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	hepatocellular carcinoma portal vein tumor thrombus percutaneous ethanol injection transarterial chemoembolization molecular targeted therapy complications
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1280837/full

Similar Items

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-11-01)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
by: Xiaomi Li, et al.
Published: (2023-08-01)

Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study
by: Ran You, et al.
Published: (2024-09-01)

TACE Combined with Portal Vein Tumor Thrombus 125I Seed Implantation in the Treatment of HCC with Hepatic Arterioportal Shunts
by: Xia WL, et al.
Published: (2024-09-01)

Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?
by: Liqing Zhang, et al.
Published: (2024-10-01)

The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
by: Zongren Ding, et al.
Published: (2024-06-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE
by: Yong Xie, et al.
Published: (2024-08-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
by: Zhang Xuexian, et al.
Published: (2024-10-01)

Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails
by: Guoliang Wang, et al.
Published: (2024-06-01)

Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study
by: Saikang Tang, et al.
Published: (2024-07-01)

Feasibility and Safety of the Clinical Outcomes of TACE Combined with Lenvatinib and PD-1 Blockades in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Exploratory Study
by: Sun W, et al.
Published: (2024-08-01)

Vigilance against gross hematuria as a rare symptom after TACE for hepatocellular carcinoma
by: Dan Zhang, et al.
Published: (2024-10-01)

TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
by: Zhihong Tang, et al.
Published: (2024-06-01)

DEB‐TACE versus cTACE for unresectable HCC with B1‐type bile duct invasion after successful biliary drainage: A propensity score matching analysis
by: Wenzhe Fan, et al.
Published: (2024-07-01)

Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma
by: Moonhyung Lee, et al.
Published: (2023-12-01)

Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-09-01)

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study
by: Song Chen, et al.
Published: (2024-07-01)

Cone-beam CT acquisition during transradial TACE made easy; use of the swivel arm board
by: Pua, Uei, et al.
Published: (2018)

Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib
by: Fang Sun, et al.
Published: (2024-04-01)

A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma
by: Wang C, et al.
Published: (2024-11-01)

Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy
by: Lei Liang, et al.
Published: (2024-12-01)

Assessment of efficacy and safety of irreversible electroporation versus TACE for treatment of difficult location hepatocellular carcinoma
by: Mohamed Hassany, et al.
Published: (2024-05-01)

Effectiveness and safety of brucea javanica oil assisted TACE versus TACE in the treatment of liver cancer: a systematic review and meta-analysis of randomized controlled trials
by: Zhi-Hai Wu, et al.
Published: (2024-06-01)

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2024-04-01)

Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
by: Dongdong Xia, et al.
Published: (2025-01-01)

AI-derived body composition parameters as prognostic factors in patients with HCC undergoing TACE in a multicenter study
by: Lukas Müller, et al.
Published: (2024-08-01)

Efficacy and safety of TACE combined with traditional Chinese medicine versus TACE alone in hepatocellular carcinoma: bayesian network meta-analysis and pharmacological mechanisms study
by: Li Chen, et al.
Published: (2024-12-01)

Efficacy of radiation plus transarterial chemoembolization and lenvatinib in hepatocellular carcinoma with portal vein tumor thrombus
by: Aoran Dong, et al.
Published: (2023-12-01)

Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment
by: Po-Ting Lin, et al.
Published: (2024-07-01)

Idarubicin-loaded degradable hydrogel for TACE therapy enhances anti-tumor immunity in hepatocellular carcinoma
by: Xiaokai Zhang, et al.
Published: (2024-12-01)

Risk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study
by: Yuzhu Wang, et al.
Published: (2024-12-01)

Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis
by: Shuai Wang, et al.
Published: (2024-05-01)

The Role of GNMT and MMP12 Expression in Determining TACE Efficacy: Validation at Transcription and Protein Levels
by: Cong T, et al.
Published: (2024-01-01)

Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial
by: Yun Hao, et al.
Published: (2024-07-01)

A Machine Learning Model for Predicting Prognosis in HCC Patients With Diabetes After TACE
by: Wu L, et al.
Published: (2025-01-01)

Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin
by: Lu SY, et al.
Published: (2024-10-01)

Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis
by: Yue Chen, et al.
Published: (2024-08-01)

Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
by: Jiang J, et al.
Published: (2024-08-01)